NVAX · Novavax Inc
United States · RS rating 98 · As of 2026-10-14
| Price | 12.64 USD |
|---|---|
| 1-day change | -1.4% |
| RS rating (overall / 1M / 3M / 12M) | 98 / 98 / 96 / 88 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 55 / 57 / 78 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +108.8% |
| Sales growth Q/Q | +108.9% |
| Distance from 52-week high | +1.4% |
| Market cap (USD) | $1.3B |